News
Clinical Trials Arena on MSN5d
ASCO25: Merck KGaA’s ADC shows safety and tolerability in colorectal cancer trialMerck KGaA’s antibody-drug conjugate (ADC), precemtabart tocentecan, has shown to be safe and tolerable in a Phase Ib trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback